Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal reported first-quarter 2026 revenue of $311.3 million, up 127% year-over-year, driven by Rezdiffra which now has over 42,000 patients on therapy. The company expanded its pipeline via a licensing agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a clinical-stage siRNA asset targeting the PNPLA3 mutation.
Key figures
- Revenue
- 311300000
- Revenue Yoy
- 127%
- Net loss
- 94400000
- Cash position
- 817900000
- Operating expenses
- 404100000
- Patients on therapy
- 42250
- Business development expenses
- 54300000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.